Prescription testosterone replacement therapy and over-the-counter natural testosterone boosters do not represent two strengths of the same approach. At Longevity Benchmark, we evaluate clinical trial registries and regulatory filings to examine what each option actually does to circulating hormone levels. Prescription therapy reliably elevates serum testosterone into physiological target ranges in clinical trials. It also produces documented clinical risks.
In contrast, most over-the-counter boosters fail to move serum testosterone in men with adequate baseline nutrition. These supplements enter retail shelves without premarket efficacy testing.
The Verdict
Testosterone Replacement Therapy vs Natural Testosterone Boosters
| Attribute | Testosterone replacement therapy | Natural testosterone boosters |
|---|---|---|
| Primary mechanism | Delivers exogenous testosterone directly into circulation via transdermal gel, intramuscular injection, or subcutaneous pellet. | Supplies botanical extracts, amino acids, and minerals intended to stimulate endogenous hormone synthesis. |
| Effect on serum testosterone | Reliably elevates total testosterone into target reference ranges (typically 350 to 750 ng/dL in trials). | Most ingredients show no significant change in healthy men. Modest increases occur mainly when a nutrient deficiency is corrected. |
| Regulatory status | Approved by the Food and Drug Administration (FDA) under specific clinical indications with published prescribing information. | Regulated under the Dietary Supplement Health and Education Act of 1994 (DSHEA) without mandatory premarket approval. |
| Clinical trial evidence base | Evaluated in large randomized controlled trials (including the 790-man Testosterone Trials and 5,246-man TRAVERSE trial) against objective endpoints. | No whole supplement products have published randomized controlled trials. The available evidence evaluates individual ingredients. |
| Effect on pituitary gonadotropins | Suppresses luteinizing hormone and follicle-stimulating hormone secretion through hypothalamic-pituitary negative feedback. | Does not suppress the hypothalamic-pituitary-gonadal axis, provided products contain no undeclared synthetic androgens. |
| Impact on male fertility | Frequently induces severe oligospermia or azoospermia by eliminating the gonadotropin signals necessary for spermatogenesis. | Does not impair spermatogenesis in unadulterated forms, but does not reverse intrinsic testicular dysfunction. |
| Documented clinical risks | Elevated blood pressure, polycythemia, nonfatal arrhythmias, fluid retention, testicular atrophy, and secondary exposure risks. | Risks stem primarily from unlisted pharmaceutical adulterants, heavy metal contamination, or product-induced liver injury. |
| Clinical monitoring standards | Endocrine guidelines outline routine surveillance of serum testosterone, hematocrit, blood pressure, and prostate-specific antigen. | No formal clinical monitoring schedules or laboratory safety protocols exist within supplement regulations. |
| Manufacturing quality control | Produced under mandatory pharmaceutical Good Manufacturing Practices with validated chemical purity and batch consistency. | Subject to dietary supplement regulations where postmarket testing frequently detects mislabeling and undeclared drugs. |
What the Supplement Category Contains
Retail testosterone boosters combine common minerals, herbal extracts, and amino acids into over-the-counter blends. Two published ingredient audits examined what these commercial formulas contain. The results were revealing.
An analysis led by Balasubramanian and colleagues (2019) evaluated the top five products on Amazon. Those listings averaged 2,761 reviews with a 4.56-star rating. The authors identified 19 unique ingredients across the formulations. They identified 191 published studies investigating the ten most frequent ingredients. Only 19% of those investigations involved human participants, with animal models accounting for 53% of the literature, in vitro experiments 15% and case reports or reviews 12%.
Among 37 human studies, 30% observed a testosterone increase. However, 46% found no effect, 3% found a decrease, and 22% were indeterminate. Customer reviews shifted after filtering by ReviewMeta. Filtered reviews showed a 91% drop in reported libido gains. Reports of improved energy fell by 59%.
A broader audit by Kuchakulla and colleagues (2021) assessed 16 popular male testosterone supplements. Products were gathered from A1 Supplements, Amazon, Vitamin Shoppe and Walmart, and the authors then evaluated 37 total ingredients against 105 randomized controlled trials. Tribulus, Eurycoma longifolia, zinc, L-arginine, aspartate, horny goat weed, and yohimbine appeared most frequently.
The authors noted that no whole supplement products had published randomized controlled trial evidence. Using criteria adapted from the American Heart Association (AHA), only 19% of ingredients earned strong positive evidence. Meanwhile, 68% received grades of C or D for conflicting, negative, or absent data.
A systematic review by Morgado and colleagues (2024) examined 52 trials covering 27 proposed booster ingredients. The authors concluded that most fail to increase total testosterone. The overall evidence base remains sparse.
The Trial Evidence Behind Common Booster Ingredients
Controlled trials evaluating individual supplement ingredients demonstrate that most compounds fail to raise serum testosterone in healthy men. D-aspartic acid gained initial popularity following an investigation by Topo and colleagues (2009). The authors administered sodium D-aspartate to 23 men for 12 days. Circulating luteinizing hormone and testosterone levels increased compared to 20 placebo controls.
Subsequent studies in trained men contradicted those findings. Willoughby and Leutholtz (2013) evaluated 28 days of supplementation in resistance-trained men. Total and free testosterone, luteinizing hormone, and estradiol remained unchanged. A trial by Melville and colleagues (2015) tested daily doses of three and six grams. In men taking six grams daily, total and free testosterone significantly decreased. A three-month study by Melville and colleagues (2017) likewise demonstrated no change in basal testosterone. The contrast stems from training status, dosage, and trial duration.
Tribulus terrestris shows a similar lack of efficacy. Neychev and Mitev (2005) provided 10 or 20 mg per kg daily to 21 healthy young men for four weeks. Serum testosterone did not differ between the active groups and controls. A systematic review by Qureshi and colleagues (2014) concluded that Tribulus is ineffective for increasing human testosterone. Apparent increases occurred almost exclusively in animal models.
Fenugreek extract presents modest, mixed trial results. Rao and colleagues (2016) administered 600 mg daily of standardized seed extract to 120 healthy men for 12 weeks. Both total and free testosterone rose relative to placebo. A meta-analysis by Mansoori and colleagues (2020) pooled four trials and found an overall effect on total serum testosterone. A larger systematic review by Isenmann and colleagues (2023) assessed seven studies including 449 participants. The authors detected a small effect for total testosterone, with a standardized mean difference of 0.32. The 95% confidence interval ranged from 0.09 to 0.55.
Ashwagandha trials show variable outcomes based on the collection method. In a trial by Wankhede and colleagues (2015), 57 young men completed eight weeks of resistance training. Subjects receiving 300 mg of extract twice daily saw serum testosterone rise by 96.19 ng/dL. Placebo participants gained 18.00 ng/dL across the same training period. A 16-week study by Lopresti and colleagues (2019) reported a 14.7% testosterone increase in overweight men. That trial measured salivary concentrations rather than serum levels. The study was also funded by the extract supplier, Arjuna Natural Ltd.
Other popular botanicals and minerals show negligible hormonal activity. Gonzales and colleagues (2003) found Maca did not affect reproductive hormone levels in adult men. Ferrando and Green (1993) gave boron to male bodybuilders for seven weeks. Testosterone rose equally in both arms due to resistance training. Boron supplementation added no measurable hormonal benefit. Nair and colleagues (2006) evaluated DHEA over two years in 87 elderly men. DHEA-sulfate levels rose, but physical performance and muscle strength did not improve. That split — no testosterone response in men, a measurable one in women — holds across the wider DHEA literature. Eurycoma longifolia demonstrated modest increases in small trials. Chan and colleagues (2021) documented testosterone increases over two weeks in 32 men. Chinnappan and colleagues (2021) observed increases at 12 weeks in men receiving 100 mg of Physta extract. Two authors on that trial were employees of Biotropics Malaysia Berhad.
What Moves Testosterone Without a Prescription
Non-pharmacological interventions alter serum testosterone primarily when they resolve a clinical micronutrient deficiency or modify body composition. Zinc supplementation illustrates this repletion pattern clearly. Prasad and colleagues (1996) evaluated zinc status and hormone levels in adult men.
In nine elderly men with marginal zinc deficiency, six months of zinc gluconate raised serum testosterone from 8.3 to 16.0 nmol/L. In the same paper, inducing zinc deficiency in four young men reduced serum testosterone from 39.9 to 10.6 nmol/L over 20 weeks. Neither trial arm tested zinc in men who already had normal zinc status. Our detailed guide explores whether does zinc increase testosterone in normal physiology.
Vitamin D follows an identical repletion mechanism. A trial by Pilz and colleagues (2011) followed 54 overweight men in a weight-reduction programme. Baseline 25-hydroxyvitamin D concentrations fell in the deficiency range, below 50 nmol/L. Men receiving 3,332 IU of vitamin D daily increased total testosterone from 10.7 to 13.4 nmol/L over one year. The placebo group showed no hormonal change.
By contrast, Lerchbaum and colleagues (2017) studied healthy men with normal baseline vitamin D. Baseline vitamin D averaged 53.3 nmol/L, and baseline total testosterone averaged 19.1 nmol/L. In that replete cohort, vitamin D supplementation produced no significant treatment effect on total testosterone. The median change measured only 0.5 nmol/L. Nutrient status determines the outcome.
Lifestyle factors also show distinct clinical limits. Weight loss and regular exercise support endogenous androgen production by reducing peripheral aromatization and insulin resistance.
How TRT Moves Serum Testosterone and Clinical Outcomes
Prescription testosterone replacement therapy directly elevates circulating testosterone to normal physiological ranges while generating measurable benefits and specific clinical harms. The Testosterone Trials, reported by Snyder and colleagues (2016), evaluated 790 men aged 65 and older. All participants presented with baseline testosterone below 275 ng/dL and clinical symptoms of hypoandrogenism.
Daily transdermal gel increased serum testosterone to the mid-normal range for healthy young men aged 19 to 40. Treatment produced moderate improvements in sexual activity, desire, and erectile function. Depressive symptoms and mood scores also showed minor improvements. However, testosterone therapy provided no significant benefit for vitality or walking distance.
Specialized substudies from the trial revealed divergent physiological outcomes. Trabecular bone mineral density at the spine increased by 7.5% compared to 0.8% on placebo, as reported by Snyder and colleagues (2017). In an anemia substudy by Roy and colleagues (2017), 54% of treated men with unexplained anemia raised hemoglobin by at least 1.0 g/dL. In contrast, Resnick and colleagues (2017) found no improvement in memory or cognitive function. Furthermore, Budoff and colleagues (2017) observed a significantly greater increase in noncalcified coronary plaque volume among men on testosterone.
Cardiovascular safety was tested formally in the TRAVERSE trial. Lincoff and colleagues (2023) randomized 5,246 men aged 45 to 80 with high cardiovascular risk and two fasting testosterone readings below 300 ng/dL. Therapy was titrated to maintain circulating levels between 350 and 750 ng/dL. Primary major adverse cardiovascular events occurred in 7.0% of the testosterone group and 7.3% of the placebo group. The hazard ratio of 0.96 met non-inferiority criteria, ruling out a 50% relative increase in cardiovascular risk.
Secondary safety outcomes showed distinct clinical concerns. The trial documented higher incidences of atrial fibrillation, acute kidney injury, and pulmonary embolism. Specific incidence rates are documented in the FDA-approved labeling for AndroGel 1.62%. The drug label documents nonfatal arrhythmias warranting intervention in 5.2% of treated patients versus 3.3% on placebo. Atrial fibrillation occurred in 3.5% versus 2.4%. Acute kidney injury occurred in 2.3% versus 1.5%. Venous thromboembolism arose in 1.7% versus 1.2%. Systolic blood pressure increased by a net between-group difference of 1.5 mm Hg.
Fracture outcomes yielded unexpected trial results. In the TRAVERSE fracture substudy, Snyder and colleagues (2024) evaluated 5,204 men over a median of 3.19 years. Clinical fractures occurred in 91 men on testosterone compared to 64 on placebo. The hazard ratio reached 1.43, with a 95% confidence interval of 1.04 to 1.97. Despite bone density increases in earlier trials, clinical fracture risk rose.
Fertility and Endocrine Axis Suppression
Exogenous testosterone suppresses pituitary gonadotropins and halts natural spermatogenesis, whereas unadulterated dietary supplements leave the endocrine axis active. The mechanism is well understood: circulating exogenous testosterone signals the hypothalamus and pituitary to halt the secretion of luteinizing hormone and follicle-stimulating hormone. Without follicle-stimulating hormone signaling Sertoli cells, sperm production declines rapidly.
Prescribing information for AndroGel warns that exogenous androgens can lead to azoospermia, testicular atrophy, and oligospermia. Contraceptive trials demonstrate the extent of this suppression. Anderson and colleagues (1996) administered 200 mg of weekly intramuscular testosterone enanthate to 33 healthy men. Sperm density declined in all 33 participants. Eighteen men achieved complete azoospermia by 20 weeks of treatment. Spermatogenesis recovery follows a variable timeline.
An integrated analysis led by Liu and colleagues (2006) pooled data from 1,549 healthy men across 30 contraceptive trials. Median recovery to 20 million sperm per mL took 3.4 months. Recovery rates reached 67% at six months and 90% at 12 months. Full recovery reached 100% within 24 months. However, this trial cohort carried strict limits. Liu and colleagues evaluated healthy eugonadal men aged 18 to 51 on supervised regimens under one year. Older men with preexisting hypogonadism cannot assume the same recovery trajectory.
Our dedicated guide examines TRT and fertility in greater depth. In contrast, over-the-counter boosters do not suppress gonadotropins when unadulterated. They also do not resolve primary testicular failure. Our analysis of enclomiphene vs TRT explores non-suppressive prescription alternatives.
Regulatory Frameworks and Label Accuracy
Prescription testosterone and over-the-counter supplements operate under fundamentally different statutory standards for safety, manufacturing, and premarket evidence. Prescription formulations undergo rigorous evaluation by the FDA before reaching the market. Approval requires prospective clinical trial evidence demonstrating efficacy and safety for specific indications. Those indications are narrow: primary testicular failure, and secondary hypogonadotropic hypogonadism.
The FDA-approved labeling for AndroGel carries an explicit Limitation of Use stating that safety and efficacy in age-related hypogonadism have not been established. In the 28 February 2025 class-wide labeling changes, the agency reaffirmed that limitation. The agency removed boxed warnings regarding cardiovascular event risk while mandating new warnings for blood pressure increases.
Dietary supplements follow an entirely different statutory route. Under 21 U.S.C. § 343(r)(6), manufacturers may market products with structure and function claims without premarket approval. Manufacturers must notify the agency within 30 days after first marketing. Every product must bear the mandatory disclaimer stating the claim has not been evaluated by the FDA. Under 21 U.S.C. § 350b, new dietary ingredients require a 75-day notification before distribution rather than formal approval. This regulatory divide creates substantial risks of misbranding and chemical contamination.
In a 15 December 2010 letter, the FDA Commissioner warned of widespread supplement adulteration. Tainted products contained prescription drugs, synthetic steroid analogues, and controlled substances. The agency cited adverse events including acute liver injury, stroke, kidney failure, pulmonary embolism, and death. The FDA documented recalls of more than 70 products marketed for sexual enhancement, more than 40 for weight loss, and more than 80 for body building.
Recent laboratory testing confirms that adulteration persists. A 26 December 2023 public notification revealed that T XTRA Strength Test Booster contained undeclared tadalafil. A 29 May 2026 public notification confirmed that Erectus Plus contained sildenafil, tadalafil, and testosterone propionate. An FDA consumer update warns that bodybuilding products frequently contain unlisted synthetic steroids and SARMs. The agency published a public warning noting risks of liver injury, acute liver failure, testicular shrinkage, and infertility from these compounds.
Clinical registries document significant organ toxicity from contaminated supplements. An investigation by the Drug-Induced Liver Injury Network (DILIN), published by Navarro and colleagues (2014), evaluated 839 liver injury cases. Supplements caused 130 cases, or 15.5% of all enrolled liver injuries. The proportion of liver injuries attributable to supplements rose from 7% to 20% during the study period. Bodybuilding supplements caused prolonged jaundice averaging 91 days in young men. Non-bodybuilding supplements led to death or liver transplantation in 13% of cases compared to 3% for conventional medications.
Advertising claims face scrutiny from the Federal Trade Commission (FTC). In 1999, the FTC challenged deceptive marketing by AST Nutritional Concepts and MET-Rx. Marketers claimed androgen precursors were completely safe without negative side effects. The settlement mandated warning labels disclosing risks of breast enlargement, testicular shrinkage, and infertility. It required competent and reliable scientific evidence for any future safety representations.
Where a Diagnosis Comes From
Neither product category is a substitute for a diagnosis. Reaching for an over-the-counter supplement can delay identifying a treatable underlying condition, and prescription therapy begins from confirmed laboratory results rather than from symptoms alone. Our guide to primary vs secondary hypogonadism sets out the guideline testing protocol in full, including which gonadotropins separate a testicular cause from a pituitary one.
Our guide on free vs total testosterone details how binding proteins affect diagnostic interpretation, and a men's hormone panel is where the baseline numbers come from. Start there before spending money on either option.
Frequently Asked Questions
Do natural testosterone boosters actually work?
Controlled clinical trials indicate that most commercial booster ingredients fail to raise serum total testosterone in healthy men. In an audit of 37 human studies on the ten most common ingredients, 30% observed an increase, 3% observed a decrease, 46% found no effect, and 22% were indeterminate. Furthermore, a systematic review of 52 trials across 27 proposed booster ingredients concluded that the majority failed to increase total testosterone. Measurable hormonal increases occur almost exclusively when single nutrients, such as zinc or vitamin D, correct an existing nutritional deficiency.
Does ashwagandha raise testosterone?
Trial evidence on ashwagandha shows mixed results depending on the study population and collection method. In an eight-week trial of young men undergoing resistance training, 300 mg of root extract twice daily was associated with an increase in serum testosterone of 96.19 ng/dL compared to 18.00 ng/dL for placebo. However, both groups exercised concurrently. Another trial in overweight men reported a 14.7% testosterone increase, but that study measured salivary concentrations rather than serum levels and was funded by the extract supplier. Systematic reviews categorize ashwagandha as possibly effective for healthy men rather than established.
Does tribulus terrestris increase testosterone?
Published clinical trials demonstrate that Tribulus terrestris does not raise serum testosterone in humans. In a controlled study of 21 healthy young men, daily supplementation with 10 or 20 mg per kg for four weeks produced no significant difference in testosterone concentrations compared to controls. The authors concluded that the herb possesses neither direct nor indirect androgen-increasing properties. A comprehensive systematic review confirmed that Tribulus is ineffective for increasing human testosterone, noting that positive findings in marketing literature rely almost entirely on animal research or multi-ingredient blends.
Are testosterone boosters regulated by the FDA?
Dietary supplements are regulated under the Dietary Supplement Health and Education Act of 1994, which does not require FDA approval before marketing. Manufacturers may market products with structure and function claims, provided they hold substantiation and notify the FDA within 30 days after first sale. They must also display a mandatory label disclaimer. For new dietary ingredients, companies must submit safety notifications 75 days prior to release. Unlike prescription testosterone, supplement manufacturers are not required to demonstrate clinical efficacy or undergo mandatory premarket testing.
Can a supplement raise testosterone as much as TRT?
No supplement has been shown in controlled clinical trials to raise serum testosterone to the magnitude achieved by prescription therapy. Prescription testosterone replacement is titrated to deliver circulating levels directly into target physiological ranges, such as 350 to 750 ng/dL in the landmark TRAVERSE trial. In contrast, whole supplement formulations lack published randomized controlled trial evidence. Even among single ingredients that demonstrate small statistical changes, such as fenugreek or ashwagandha, the observed shifts do not match the predictable, sustained elevations produced by pharmaceutical hormone replacement.
Do testosterone boosters affect fertility the way TRT does?
Unadulterated over-the-counter supplements do not suppress pituitary gonadotropins or impair sperm production. In contrast, prescription testosterone replacement delivers exogenous androgens that trigger negative feedback on the hypothalamus and pituitary gland. This feedback suppresses luteinizing hormone and follicle-stimulating hormone, commonly resulting in severe oligospermia or azoospermia. However, over-the-counter products present indirect fertility risks if they contain undisclosed pharmaceutical contaminants. FDA laboratory testing has identified synthetic anabolic steroids and SARMs in illicit bodybuilding supplements, both of which induce profound testicular suppression.
What did trials find for D-aspartic acid?
An initial trial in 23 healthy men reported that daily sodium D-aspartate for 12 days increased luteinizing hormone and testosterone. However, subsequent trials failed to replicate that effect. A 28-day study in resistance-trained men found no changes in total or free testosterone, luteinizing hormone, or estradiol. In a dose-comparison trial, a daily intake of six grams actually reduced total and free testosterone in trained men. A three-month randomized trial likewise found no change in basal testosterone levels, indicating that D-aspartic acid is ineffective in resistance-trained cohorts.
Does zinc supplementation raise testosterone in healthy men?
Zinc supplementation increases serum testosterone only in individuals who are clinically zinc-deficient. In a classic study, providing oral zinc gluconate for six months to nine elderly men with marginal zinc deficiency raised serum testosterone from 8.3 to 16.0 nmol/L. In the same paper, restricting dietary zinc in four young men dropped testosterone from 39.9 to 10.6 nmol/L. However, systematic reviews covering multiple clinical trials confirm that zinc supplementation fails to raise total testosterone in men who maintain adequate baseline zinc levels through diet.